1 Erratum to: Am J Cardiovasc Drugs DOI 10.1007/s40256-017-0216-5
Section 6.3, para 5, lines 15–17 which previously read:
The mean percent changes in LDL-C, TG and apo B levels from baseline were −21, −14 and −23%, respectively, in the rhSA-treated group.
Should read:
The mean percent changes in LDL-C, TG and apo B levels compared with placebo were −21, −14 and −23%, respectively, in the rhSA-treated group.
Section 6.3, para 6, lines 1–3 which previously read:
Adverse events were mild and similar in the treated and placebo groups, and included headache (10%), pyrexia (7%), diarrhea (6%), runny nose (4%) and nausea (3%).
Should read:
Adverse events were mild and similar in the treated and placebo groups, and included headache (n = 10), pyrexia (n = 7), diarrhea (n = 6), runny nose (n = 4) and nausea (n = 3).
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1007/s40256-017-0216-5.
Rights and permissions
About this article
Cite this article
Maciejko, J.J. Erratum to: Managing Cardiovascular Risk in Lysosomal Acid Lipase Deficiency. Am J Cardiovasc Drugs 17, 233 (2017). https://doi.org/10.1007/s40256-017-0228-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40256-017-0228-1